JP Morgan downgrades NeuroPace to Neutral and cuts price target to $9
According to TradingView, JP Morgan downgraded NeuroPace shares to Neutral from Overweight and lowered its price target from $20 to $9, a 55.0% cut.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
JP Morgan downgraded NeuroPace to Neutral from Overweight and reduced its price target from $20 to $9, a 55.0% decrease. The bank's new target implies a 25.1% downside from the November 12 close of $12.02. The information was published by TradingView, citing data from Benzinga.
why it matters
A downgrade from a major bank reflects a revised outlook on the stock and can weigh on investor sentiment toward the company. The news concerns a single company and does not change the broader market picture.
tags
instruments
sources
- JP Morgan downgrades NeuroPace to Neutral from Overweight, lowers price target to $9 from $20 — TradingView, 13 November 2026 at 14:28 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗